437“ƒ

2009 Aida et al. Caries Res 2006;40 2000 100 % 78.7 88.0 96.6 98.8 98.8 98.8 100.0 100.0 100 75 69.4 50 75.3 74.8 73.3 73.1 73.0 72.4 71.8 71.7 51.7 40.2 69.4 68.8 73.6 25 22.3 32.8 21.9 22.9 22.1

The Heart Healthy Tocotrienol Complex Tocomin SupraBio

The Heart Healthy Tocotrienol Complex Tocomin SupraBio The Heart Healthy Tocotrienol Complex Tocomin SupraBio 1. Fact Sheet No. 317; World Health Organization (WHO), 2007 2. LLOYD-JONES D. et al. Circulation

表1.eps

Vol.1 C ontents 1 2 cell-free EMBO J Proc. Natl. Acad. Sci. USA NatureEMBO J 3 RNA NatureEMBO J Nature EMBO J 4 5 HCV HCV HCV HCV RNA HCV in situ 6 7 8 Nat Struct Mol Biol J Biol Chem Nat Commun J Virol

Establishment and progress of Sendai virus engineering 2) Schnell, M. J., Mebatsion, T., Conzelmann, K.-K.: EMBO J., 13,4195-4203(1994) 3) Kato, A. et al.: Genes Cells, 1, 569-579 (1996) 4) Nagai,

がん患者の終末期ケアにおける通所リハビリテーションの役割　介護保険によるがん終末期ケアの可能性

2 3 3 6 7 49 53 13 61 22 27 65 68 34 47 71 73 4 5 7 6 8 9 10 11 12 13 14 15 44 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4

日本赤十字看護学会誌　第7巻第1号　若年妊婦の妊娠・分娩・育児期におけるケアニーズの分析－ドゥーラの役割の検討に向けて－

Various function and toxicity of iron Key words 1) Hentze, M. W. et al: Cell, 117, 285-297 (2004) 2) Ganz, T.: Blood, 102, 783-788 (2003) 3) Nemeth, E. et al.: Science, 306, 2090-2093 (2004) 4) Hentze,

2 (1) (2) SCI 2 SCI 2 24 2 12 2

2004 (1) (2) (2) (3) (1) 1 (2) (3) 2 (1) (2) SCI 2 SCI 2 24 2 12 2 100% / 16 2002 2003 http://lin.lin.go.jp/alic/month/dome/1997/nov/chousa.htm (05 612 1315 1618 1922 2329 3039 4049 5059 60 ) =10 b g 1

™·”õ/sec3_p63_84/fiü“eflÅ

Section3 64 1 65 Section 3 1 2 3 4 5 6 7 8 9 10 11 12 13 14 1 Babara E. Ainsworth et al. Med. Sci. Sports. Exevc.1993 66 67 Section 3 1 10 9 8 1 2 3 4 7 6 5 6 7 5 1 2 3 4 68 69 Section 3 2 70 Section 3

A-FR

11 12 > 17 13 14 http://store.uniqlo.com/jp/ http://www.uniqlo.com/jp/corp/customer 15 16 LONDON PARIS SHANGHAI 18 100 80 94 60 54 40 39 30 20 9 11 9 14 0 02 03 04 05 06 07 08 09 HONG KONG SEOUL NEW YORK

442号

０５００７１２，京大総合人間学部広報／広報

2016select追加小冊子_0704出稿0706修正.indd

-JPN3 -JPN3 -G1 -G1 -G3 -OP -OP -OP -G3 -G3 -G3 -G3 -G3 -L -L -G1 -JPN1 -OP -G3 -OP -JPN2 -G3 -JPN1 -G3 -G3 -L-L -L -L -G3 -L -L -G2 -L -G3 -G1 -G2 -G2 -G3 -L -G1 -G2 -G3 -G1 -G3 -L -L -L -G3 -G3 -L -G1

Short Review Hidenori Takagi, Fumio Takaiwa, E-mail : [email protected] 13) Hirahara, K. et al. : J. Allergy Clin. Immunol., 102, 961-967 (1998) 14) Takagi, H. et al.: Proc. Natl. Acad. Sci.

Microsoft PowerPoint - masayukiakiyama_20141103.pptx

untitled

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Int J Radiat Oncol Biol Phys 49 Cancer 101 Int J Radiat Oncol Biol Phys 60 Chest 124 Int J Radiat Oncol Biol Phys 56 Int J Radiat Oncol Biol Phys 49 Chest 124 Int J

VOL33NO.3/2010 A B A B p-erk1/2 Time (min) 0 1 2 5 10 15 30 60 90 120 Erk1/2 Time (min) 0 1 2 5 10 15 30 60 90 120 p-vasp VASP C D enos/gapdh x-fold vs sham 2.0 1.5 1.0 0.5 * 0 ANP (-) (+) (-)

4) H. Takayama et al.: J. Med. Chem., 45, 1949 (2002). 5) H. Takayama et al.: J. Am. Chem. Soc., 112, 8635 (2000). 6) H. Takayama et al.: Tetrahedron Lett., 42, 2995 (2001). 9) M. Kitajima et al: Chem.

; cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml Mφ 6 7, 8 9

32, 21-25, 2012 CASLE 1 1 80 26 6 5 4 cm 1 2 CEA 3 4 CEA 2 44 22 2 3 1.5 cm 22 1. 1 ; 6 5 4 cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml 0-40 5 Mφ 6 7, 8 9 23 6. ; 9. ; 7. ; 10. ; 8. 7 10 CK3 CK3 24 1,2 3 2 8% 4,5

Complex sleep apnea syndrome and sleep disordered breathing in patients with cardiovascular disease V o l. 4 1 N o. 3 ( 2 0 0 9 ) V o l. 4 1 N o. 3 ( 2 0 0 9 ) V o l. 4 1 N o. 3 ( 2 0 0 9 ) Sleep J Clin

日本皮膚科学会第121巻第9号

Appl Nurs Res Wound Repair Regen Int Wound J Adv Skin Wound Care Ostomy Wound Manage Wound Repair Regen Int J Nurs Stud JAdvNurs Visual Dermatology J Adv Nurs Appl Nurs Res Cochrane Database Syst Rev

2

1 2 3 4 5 6 7 8 9 10 11 12 13 14 10mSv 15 16 17 4.46 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 3.8 2.07 2.91 1.37 2.3 1.31 1.84 1.56 1.2 1.33 2.03 0.5 1000 4000mSv 1000 4000mSv Preston et al. Radiat Res 168: 1 64,

105†^Ÿ_Ł¶†^åM“è‡Ù‡©.pwd

et al et al et al et al et al et al et al et al et al et al et al 43 44 45 46 47 48 49 50 51 52 53 54 J. Hydrol J. Hydrol J. Hydrol J. Hydrol Isotope Techniques in Groundwater Hydrology J. Hydrol J. Hydrol

24 25

日本皮膚科学会雑誌第122巻第2号

J Dermatol Sci Vitam Horm NEnglJMed Lancet J Clin Invest Antitoxid Redox Signal Diabetes Metab Res Rev Diabetes Care Diabet Med Diabetes care Diabetes Care J Foot Ankle Surg Wound Repair Regen Lancet Foot

et al No To Shinkei Clin Neurol Neurology et al J Neurosurg et al Arch Neurol et al Angiology

37 Recommendations for the Management of Moyamoya Disease A Statement from Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) Research on intractable diseases of the

2

FAX-2840 2 http://solutions.brother.co.jp/ https://myportal.brother.co.jp/ Version 0 JPN 2 3 4 5 2 3 4 6 2 3 2 3 2 3 2 3 7 8 2 3 2 3 9 2 3 2 3 2 3 2 3 0 2 3 2 3 2 3 4 2 3 2 2 3 2 5 6 2 3 2 3 2 3 2 3 7

untitled

2005 10 13 Dr. RGA 19602000 10 Australian Institute of of Health and and Welfare 2004 ABS Cat. Cat. No. No. 3201.0; AIHW National Population Database 1875 2 211997 8 122164 http://www.wowzone.com/calment.htm

VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3

VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3 2 OptiView ALK D5F3 11 10 79.3%31% 18% 80 85NSCLC 40% 1,2 1 1018 ALK ALK 2 ALK 3 5% ALK EML4 EML4-ALK Coild-Coil ALK ALK 3,4,5 2 6 EGFR 50%

日本目録規則1987年版改訂2版第2章図書改定案

2.0.1 2.0.2 2.0.3 2.0.4 2.0.5 2.0.6 2.1.1 2.1.2 2.1.3 2.1.4 2.1.5 2.2.1 2.2.2 2.2.3 2.2.4 2.4.1 2.4.2 2.4.3 2.4.4 2.5.1 2.5.2 2.5.3 2.5.4 2.6.1 2.6.2 2.6.3 2.6.4 2.6.5 ISSN 2.6.6 2.6.7 2.7.1 2.7.2 2.7.3

ｎｓｇ０２－１３／ｋｙ０４５０５９３０１６０００３３２１０

φ φ φ φ κ κ α α μ μ α α μ χ et al Neurosci. Res. Trpv J Physiol μ μ α α α β in vivo β β β β β β β β in vitro β γ μ δ μδ δ δ α θ α θ α In Biomechanics at Micro- and Nanoscale Levels, Volume I W W v W

2007050781......_.L.O...z.W

a s d f g a s d f g h j k l 0 in vitro in vivo in vitro in vivo in vivo in vivo in vitro Metabolism Metabolism Endocr Endocr Endocrinol Ann NYA cad Sci J clin Endocr Metab

胃癌診療 -内視鏡治療と予防の最前線-

K net 21 5 28 10-20 5 100 32 K net 19 1 18 - - K net 21 5 28 2 2 RCT LECS NOTES 19 2 Narrow Band Imaging Light Penetration Depth Light penetration depth within the tissue highly depends on the wavelength.

ライフサイエンス関連　コラーゲン・ゼラチン製品案内　2015.12

3 mg/ml ph 3 4 8 1 Type I-A Type I-P Type I-A Type I-C Type III Type III Type IV Type IV TEL 072-820-3079 FAX 072-820-3095 4 8 4 Type I-A 20mL 1 F-12 MEM 5mL 1 4mL 5 10F-12MEM DFDME F-12 1 1199 5 DMERPMI-1640

化学療法剤の適切な使い方について

1 2 3 4 5 6 7 Che E, in Cancer: Principles & Practice of Oncology (7th ed) in Devita, 2005 Marangolo M, Oncol Rep, 2006 hryniuk WM, Important Adv Oncol, 1988 8 Cancer: Principles & Practice of Oncology

日本皮膚科学会雑誌第121巻第11号

β Clin Rheumatol Arthritis Rheum Am J Cardiol J Rheumatol J Rheumatol Arthritis Rheum Arthritis Rheum Arthritis Rheum Rheumatology Oxford Rheumatology Oxford Br J Dermatol Arch Dermatol Ann Rheum Dis

1) van Meer, G., Op den Kamp, J. A.: J. Cell. Biochem., 19, 193-2040982) 2) Gaffet, P., Bettache, N., Bienvenue, A.: Biochemistry, 34, 6762-6769(1995) 3) Sims, P. J., Wiedmer, T.: Thromb. Haemost., 86,

日本皮膚科学会雑誌第122巻第7号

Br J Dermatol NEnglJ Med 尋常性白斑診療ガイドライン 図 1 先天性白斑 白皮症の病型分類 図 2 後天性白斑 白皮症の病型分類 の尋常性白斑患者で家系内発症がみられることより 3 5 れらの合併が染色体 17p13 における一塩基多型に起 非分節 因し その候補遺伝子の一つが自然免疫に重要とされ 型に含まれる汎発型には甲状腺に対する抗サイログロ る NALP1 遺伝子であると報告している6

432..

et al., et al., et al., år är ön Nature Rep. int. Whal. Commn Mar. Mamm. Sci ICES Journal of Marine Science år år önlobodon carcinophaguscanadian Journal of Fisheries and Aquatic Sciences Rep. int.

MI( MI() 100% 100% 75% 75% 33% 75% 60% 40% 25% 60% 1 2 3 4 5 6 7 8 9 () 12 () () () !! 1. 2. 3. 1. 2. () () () 3-5% ex. ex. 11 ex. () ex. ex. : ex. : (insula) () () ( 2009 ) () ( ) YES! ()

Single slice helical CT CT 1 2005 1 4 1. CT Anti-Lung Cancer Association: ALCA 1-5) 1993 9 10 ALCA (Nawa 6) ) single slice helical CT 10mm CT 2. 1 (http://www.thoracic-ctscreening.org/jpn/index.html )

1315 (15)

(14) 1315 (15) 1316 (16) 1317 (17) 1318 (18) 1319 (19) 1320 (20) 1321 (21) 1322 quinidine, disopyramide, and procainamide in isolated atrial myocytes : Mediation by 2) Inoue H, et al: Effects of pentisomide

Kazumitsu Ueda, [Department of Applied Life Science, Kyoto University Graduate School of Agriculture, Kitashirakawa, Sakyo-ku, Kyoto 606-01, Japan] Molecular Mechanisms for Drug Transport by MDR1/P-glycoprotein

01_朝倉他.indd

Msx2

第６号－２／８）最前線（大矢）

最前線 免疫疾患における創薬標的としてのカリウムチャネル 大矢 進 Susumu OHYA 京都薬科大学薬理学分野教授 異なる経路を辿る １つは マイトジェンシグナル 1 はじめに を活性化し 細胞増殖が促進されるシグナル伝達経 路 図１A 右 であり もう１つはカスパーゼやエ 神 経 筋 の よ う な 興 奮 性 細 胞 で は カ リ ウ ム ンドヌクレアーゼ活性を上昇させ アポトーシスが K

Folia Pharmacol. Jpn mg/14 ml mg/ ml Genentech, Inc. Genentech HER human epidermal growth factor receptor type HER - HER HER HER HER

Folia Pharmacol. Jpn. 143 420 mg/14 ml 1 2 3 4 mg/ ml Genentech, Inc. Genentech HER human epidermal growth factor receptor type HER - HER HER HER HER HER KPL- HER BO HER CLEOPATRA HER HER 1. HER HER EGFR

P1-20**

(1982) 4) Bennett, J. W. : in The 10th International Congress for Culture Collections. (Okuda, T., Bennett, J. W. ed.), pp. 54-57(2004) 5) Machida, M.: Adv. Appl. Microbiol. 51, 81-106 (2002) 6) Florea,

3 467 14 1 4 2 1 1 23 4 9 1 0 0 0 14 18 10 5 2 1 1 37 5 3 1 5 2 16 0 0 0 0 0 0 1 0 0 4 2 7 6 3 1 9 4 23

466 2 3 467 14 1 4 2 1 1 23 4 9 1 0 0 0 14 18 10 5 2 1 1 37 5 3 1 5 2 16 0 0 0 0 0 0 1 0 0 4 2 7 6 3 1 9 4 23 468 4 Jiang R (1990) n=190 () (1989) n=3 No authors listed (1978) n=1006 71.8 Ballegaard S